RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T16:10:00Z
MedMira Second Quarter 2023 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2022)
Sat 08 Apr 23, 12:55 PMMedMira Reports Second Quarter Results FY2023
Tue 04 Apr 23, 01:00 AMMedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
Wed 11 Jan 23, 01:22 PMMedMira Reports First Quarter Results FY2023
Sat 31 Dec 22, 03:00 AMMedMira Introduces VYRA TriDemic
Fri 30 Dec 22, 02:00 AM| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Income before tax | -2.67566M | -1.83157M | -0.67580M | -2.04539M | -2.10645M |
| Minority interest | - | - | - | - | - |
| Net income | -2.67566M | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Selling general administrative | 0.84M | 0.73M | 0.49M | 1.17M | 0.91M |
| Selling and marketing expenses | 0.20M | 0.01M | 0.04M | 0.04M | 0.13M |
| Gross profit | 0.30M | 0.30M | 1.72M | 0.57M | 0.42M |
| Reconciled depreciation | 0.21M | 0.21M | 0.21M | 0.19M | 0.02M |
| Ebit | -1.79014M | -1.27954M | -0.02250M | -1.31976M | -1.29603M |
| Ebitda | -1.57724M | -1.06724M | 0.19M | -1.12659M | -1.27717M |
| Depreciation and amortization | 0.21M | 0.21M | 0.21M | 0.19M | 0.02M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -1.94432M | -1.45322M | -0.18423M | -1.30016M | -1.29603M |
| Other operating expenses | 2.21M | 2.22M | 2.14M | 2.22M | 1.82M |
| Interest expense | 0.89M | 0.55M | 0.65M | 0.73M | 0.81M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | -0.89752M | -0.56203M | -0.68169M | -0.74523M | -0.81041M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.15M | 0.17M | 0.16M | -0.01960M | -0.15300M |
| Total revenue | 0.43M | 0.95M | 2.14M | 0.92M | 0.53M |
| Total operating expenses | 2.08M | 1.57M | 1.72M | 1.87M | 1.72M |
| Cost of revenue | 0.13M | 0.65M | 0.42M | 0.35M | 0.10M |
| Total other income expense net | -0.73134M | -0.37835M | -0.49156M | -0.74523M | -0.81041M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -2.67566M | -1.83157M | -0.67580M | -2.04539M | -2.10645M |
| Net income applicable to common shares | - | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Total assets | 3.65M | 3.83M | 3.89M | 3.40M | 0.25M |
| Intangible assets | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | - |
| Total liab | 18.68M | 16.19M | 19.61M | 18.96M | 13.77M |
| Total stockholder equity | -15.03166M | -12.35600M | -15.72390M | -15.56235M | -13.51696M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | 0.61M | 1.23M | 1.30M | 2.07M |
| Common stock | - | 68.35M | 63.90M | 63.42M | 63.42M |
| Capital stock | 68.35M | 68.35M | 63.90M | 63.42M | 63.42M |
| Retained earnings | -97.95910M | -95.28345M | -93.45187M | -92.77607M | -90.73069M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 0.01M | 0.03M | - | 0.40M | 0.09M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.73M | 14.14M | 17.41M | 15.81M | 13.77M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 7.25M | 6.11M | 9.23M | 9.07M | 8.52M |
| Short term debt | - | - | - | - | 8.61M |
| Short long term debt | 6.14M | 6.10M | 9.19M | 8.62M | 8.61M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | 14.58M | 13.82M | 13.79M | 13.79M |
| Property plant equipment | - | 2.17M | 2.31M | 2.48M | 0.00674M |
| Total current assets | 1.69M | 1.66M | 1.58M | 0.91M | 0.25M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | -12.35850M | -15.72640M | -15.56485M | -13.51947M |
| Short term investments | - | - | - | - | - |
| Net receivables | 1.26M | 1.37M | 1.25M | 0.21M | 0.04M |
| Long term debt | 1.12M | 0.04M | 0.04M | 0.85M | - |
| Inventory | 0.18M | 0.20M | 0.24M | 0.22M | 0.11M |
| Accounts payable | 3.26M | 2.75M | 2.70M | 2.31M | 1.75M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | 0.00674M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.96M | 2.17M | 2.31M | 2.48M | 0.00674M |
| Capital lease obligations | 2.01M | 2.16M | 2.30M | 2.44M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-07-31 | 2022-07-31 | 2021-07-31 | 2020-07-31 | 2019-07-31 |
| Investments | -0.00127M | -0.06972M | -0.03655M | -0.10188M | 0.00334M |
| Change to liabilities | - | -0.57187M | 0.32M | 1.06M | 0.13M |
| Total cashflows from investing activities | - | -0.06972M | -0.03655M | -0.10188M | 0.00334M |
| Net borrowings | - | 0.35M | -0.37493M | 0.73M | 1.03M |
| Total cash from financing activities | 1.25M | 1.99M | 0.14M | 0.73M | 1.03M |
| Change to operating activities | - | 0.39M | 0.70M | 0.76M | 0.92M |
| Net income | -2.67566M | -1.83158M | -0.67580M | -2.04539M | -2.10645M |
| Change in cash | -0.02028M | 0.03M | -0.40186M | 0.31M | 0.09M |
| Begin period cash flow | 0.03M | 0.00000M | 0.40M | 0.09M | 0.00000M |
| End period cash flow | 0.01M | 0.03M | 0.00000M | 0.40M | 0.09M |
| Total cash from operating activities | -1.26775M | -1.88396M | -0.50464M | -0.31590M | -0.94113M |
| Issuance of capital stock | 0.00000M | 1.67M | 0.52M | - | - |
| Depreciation | 0.21M | 0.21M | 0.21M | 0.19M | 0.02M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.02M | 0.03M | -0.01319M | -0.11633M | 0.08M |
| Change to account receivables | -0.01117M | 0.00056M | -1.04286M | -0.16867M | 0.00912M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 1.40M | 0.53M | 0.06M | 1.31M | 1.16M |
| Change to netincome | - | - | - | - | -0.01250M |
| Capital expenditures | 0.00127M | 0.07M | 0.04M | 0.10M | 0.10M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 1.20M | -0.26467M | -0.03664M | 1.54M | 1.16M |
| Stock based compensation | - | - | - | - | 0.00000M |
| Other non cash items | -0.04849M | 0.46M | 1.09M | 0.84M | -0.01250M |
| Free cash flow | -1.26902M | -1.95367M | -0.54119M | -0.41778M | -0.94113M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MIR MedMira Inc |
- -% | 0.08 | - | - | 164.76 | - | 180.27 | -80.0318 |
| NGEN NervGen Pharma Corp |
0.64 26.02% | 3.10 | - | - | - | 14.75 | -4.5367 | |
| ARCH Arch Biopartners Inc |
0.01 0.59% | 1.71 | - | - | 93.45 | - | 53.05 | -97.5918 |
| COV Covalon Technologies Ltd. |
-0.04 1.16% | 3.40 | - | - | 3.38 | 4.55 | 3.09 | 2136.68 |
| NRX NurExone Biologic Inc. |
-0.01 1.35% | 0.73 | - | - | - | 12.86 | -7.2365 |
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. In addition, the company offers VYRATM TriDemic antigen rapid test that distinguishes the three respiratory viruses, such as SARS-CoV-2, influenza, and respiratory syncytial virus that exhibit similar symptoms. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
155 Chain Lake Drive, Halifax, NS, Canada, B3S 1B3
| Name | Title | Year Born |
|---|---|---|
| Mr. Hermes Chan | Co-Founder, CEO, Pres & Director | NA |
| Mr. Markus M. Meile | Chief Financial Officer | NA |
| Stewart McKelvey | Legal Counsel | NA |
| Dr. Kevin D. Jones | Head of Commercialization and Sr. Director of Sales & Marketing | 1969 |
| Mr. Hermes Chan | Co-Founder, CEO, President & Director | NA |
| Dr. Sam Ratnam | Director of Scientific & Regulatory Affairs | NA |
| Dr. Kevin D. Jones | Head of Commercialization and Senior Director of Sales & Marketing | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...